2Seventy Bio Company Insiders
| TSVT Stock | USD 2.62 0.13 5.22% |
2Seventy Bio employs about 274 people. The company is managed by 19 executives with a total tenure of roughly 640 years, averaging almost 33.0 years of service per executive, having 14.42 employees per reported executive. Breaking down 2Seventy Bio's management performance can provide insight into the firm performance.
2Seventy |
2Seventy Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.1902) % which means that it has lost $0.1902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5189) %, meaning that it created substantial loss on money invested by shareholders. 2Seventy Bio's management efficiency ratios could be used to measure how well 2Seventy Bio manages its routine affairs as well as how well it operates its assets and liabilities.2Seventy Bio Workforce Comparison
2Seventy Bio is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 7,026. 2Seventy Bio holds roughly 274 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.07) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.99) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.99. 2Seventy Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 2Seventy Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on 2Seventy Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, 2Seventy Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
2Seventy Bio Notable Stakeholders
A 2Seventy Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as 2Seventy Bio often face trade-offs trying to please all of them. 2Seventy Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting 2Seventy Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Nick Leschly | President Director | Profile | |
| Teresa JD | General VP | Profile | |
| Michael Certo | VP Editing | Profile | |
| Susan AbuAbsi | Chief Officer | Profile | |
| DPHIL Phil | Chief Officer | Profile | |
| Anna TruppelHartmann | Chief Officer | Profile | |
| Victoria Eatwell | Chief Officer | Profile | |
| Steven Shamah | Head Research | Profile | |
| MS MD | Head Devel | Profile | |
| Jessica Snow | Senior Operations | Profile | |
| Anna MD | Chief Officer | Profile | |
| Nicola Heffron | Chief Officer | Profile | |
| William III | Chief Officer | Profile | |
| Jenn Snyder | Senior Affairs | Profile | |
| MBA III | Principal Officer | Profile | |
| Steven MD | Chief Officer | Profile | |
| Kathleen Wilkinson | Head Culture | Profile | |
| Kerri Jensen | Head Culture | Profile | |
| Vicki Eatwell | Chief Officer | Profile |
About 2Seventy Bio Management Performance
The success or failure of an entity such as 2Seventy Bio often depends on how effective the management is. 2Seventy Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of 2Seventy management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the 2Seventy management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2Seventy Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people.
Please note, the imprecision that can be found in 2Seventy Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of 2Seventy Bio. Check 2Seventy Bio's Beneish M Score to see the likelihood of 2Seventy Bio's management manipulating its earnings.
2Seventy Bio Workforce Analysis
Traditionally, organizations such as 2Seventy Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare 2Seventy Bio within its industry.2Seventy Bio Manpower Efficiency
Return on 2Seventy Bio Manpower
| Revenue Per Employee | 366.4K | |
| Revenue Per Executive | 5.3M | |
| Net Loss Per Employee | 794.1K | |
| Net Loss Per Executive | 11.5M | |
| Working Capital Per Employee | 649.6K | |
| Working Capital Per Executive | 9.4M |
Additional Tools for 2Seventy Stock Analysis
When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.